

134 - Drug interactions

Drug interactions

Depression and anxiety disorders CHAPTER 3 15. Roehrs T, et al. Drug-related sleep stage changes: functional significance and clinical relevance. *Sleep Med Clin* 2010; 5:559-570. 16. Yue JL, et al. Efficacy and tolerability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis. *Sleep Med Rev* 2023; 68:101746. 17. Wilson S, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. *J Psychopharmacol* 2019; 33:923-947. 18. Hallahan BP, et al. Benzodiazepine and hypnotic prescribing in an acute adult psychiatric in-patient unit. *Psychiatr Bull* 2009; 33:12-14. 19. Mahomed R, et al. Prescribing hypnotics in a mental health trust: what consultants say and what they do. *Pharmaceutical J* 2002; 268:657-659. 20. Benasi G, et al. Benzodiazepines as a monotherapy in depressive disorders: a systematic review. *Psychother Psychosom* 2018; 87:65-74. 21. Shiwaku H, et al. Benzodiazepines reduce relapse and recurrence rates in patients with psychotic depression. *J Clin Med* 2020; 9:1938. 22. Ogawa Y, et al. Antidepressants plus benzodiazepines for adults with major depression. *Cochrane Database Syst Rev* 2019; 6:CD001026. 23. Department of Health and Social Care. A National Service Framework for Mental Health: Modern standards and service models. London: DHSC; 1999 (last accessed February 2025); <https://www.gov.uk/government/publications/quality-standards-for-mental-health-services>. 24. Bushnell GA, et al. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014. *JAMA Psychiatry* 2017; 74:747-755. 25. Patel MX, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation. *J Psychopharmacol* 2018; 32:601-640. 26. Zaman H, et al. Benzodiazepines for psychosis-induced aggression or agitation. *Cochrane Database Syst Rev* 2017; 12:CD003079. 27. Dold M, et al. Benzodiazepines for schizophrenia. *Cochrane Database Syst Rev* 2012; 11:CD006391. 28. Sim F, et al. Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. *J Psychopharmacol* 2015; 29:212-223. 29. Paton C, et al. Benzodiazepines in schizophrenia. Is there a trend towards long-term prescribing? *Psychiatr Bull* 2000; 24:113-115. 30. Dold M, et al. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. *Eur Neuropsychopharmacol* 2013; 23:1023-1033. 31. Bergman H, et al. Benzodiazepines for antipsychotic-induced tardive dyskinesia. *Cochrane Database Syst Rev* 2018; 1:CD000205. 32. Huff C, et al. Enduring neurological sequelae of benzodiazepine use: an Internet survey. *Ther Adv Psychopharmacol* 2023; 13:20451253221145561. 33. Crowe SF, et al. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. *Arch Clin Neuropsychol* 2017; 33:901-911. 34. Poly TN, et al. Association between benzodiazepines use and risk of hip fracture in the elderly people: a meta-analysis of observational studies. *Joint Bone Spine*

2020; 87:241–249. 35. Barbone F, et al. Association of road-traffic accidents with benzodiazepine use. *Lancet* 1998; 352:1331–1336. 36. Rudisill TM, et al. Medication use and the risk of motor vehicle collisions among licensed drivers: a systematic review. *Accid Anal Prev* 2016; 96:255–270. 37. Albrecht B, et al. Benzodiazepine use and aggressive behaviour: a systematic review. *Aust N Z J Psychiatry* 2014; 48:1096–1114. 38. Kim DH, et al. Use of hypnotics and risk of cancer: a meta-analysis of observational studies. *Korean J Fam Med* 2018; 39:211–218. 39. Brandt J, et al. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. *Drugs R D* 2017; 17:493–507. 40. Peng TR, et al. Hypnotics and risk of cancer: a meta-analysis of observational studies. *Medicina (Kaunas)* 2020; 56:513. 41. Wu CC, et al. Benzodiazepine use and the risk of dementia in the elderly population: an umbrella review of meta-analyses. *J Pers Med* 2023; 13:1485. 42. Mula M. The safety and tolerability of intranasal midazolam in epilepsy. *Expert Rev Neurother* 2014; 14:735–740. 43. Midazolam oral transmucosal route: an alternative to rectal diazepam for some children. *Prescrire Int* 2013; 22:173–177. 44. Penninga EI, et al. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication: a systematic review with meta-analyses of randomised trials. *Basic Clin Pharmacol Toxicol* 2016; 118:37–44.

Revision #1

Created 2026-01-04 20:15:12 UTC by Omar Ayman

Updated 2026-01-04 20:15:12 UTC by Omar Ayman